NASDAQ · PDSBHealthcarePharmaceuticals

PDS Biotechnology news

$0.7429−3.00%

Close Sep 29, 2026 · split-adjusted

Articles · 30 days1English, de-duplicated

Positive1100% of coverage

Neutral00%

Negative00% of coverage

About PDS Biotechnology

No recent articles focused on PDS Biotechnology.

Also mentions PDSB

Articles that tag PDSB but are mainly about other companies.

Head and Neck Squamous Cell Carcinoma (HNSCC) - Market Insights, Epidemiology, and Market Forecast - 2036 | Set to Reach $2.56 Billion as HPV-Targeted Vaccines Reshape Care

GlobeNewswire Inc.Sep 30, 4:54 AM ET▲ Positive

Versamune HPV (PDS0101), an HPV-directed therapeutic vaccine candidate, is highlighted as a notable program with early evidence suggesting stronger activity in combination with PD-1 inhibitors.

Correction: Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight

GlobeNewswire Inc.Jul 21, 1:00 PM ET▲ Positive

Developing Versamune HPV, a therapeutic cancer vaccine with notable clinical potential and considered among the most promising investigational therapies for HPV-positive HNSCC.

Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight

GlobeNewswire Inc.Jul 13, 1:00 PM ET▲ Positive

Developing Versamune HPV and PDS0101, therapeutic cancer vaccines with demonstrated clinical potential in HNSCC. The company is well-positioned in the growing therapeutic vaccine segment.

Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology